201 related articles for article (PubMed ID: 15627029)
1. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
[TBL] [Abstract][Full Text] [Related]
3. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
[TBL] [Abstract][Full Text] [Related]
5. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.
Cherry CL; Lal L; Thompson KA; McLean CA; Ross LL; Hernandez J; Wesselingh SL; McComsey G
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):263-7. PubMed ID: 15735442
[TBL] [Abstract][Full Text] [Related]
6. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
[TBL] [Abstract][Full Text] [Related]
7. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
[TBL] [Abstract][Full Text] [Related]
9. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
10. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
[TBL] [Abstract][Full Text] [Related]
11. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
[TBL] [Abstract][Full Text] [Related]
12. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
[TBL] [Abstract][Full Text] [Related]
14. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G
Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539
[TBL] [Abstract][Full Text] [Related]
15. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Caron M; Auclair M; Lagathu C; Lombès A; Walker UA; Kornprobst M; Capeau J
AIDS; 2004 Nov; 18(16):2127-36. PubMed ID: 15577645
[TBL] [Abstract][Full Text] [Related]
16. From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
Curran A; Ribera E
Expert Opin Drug Saf; 2011 May; 10(3):389-406. PubMed ID: 21235431
[TBL] [Abstract][Full Text] [Related]
17. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.
Hoy JF; Gahan ME; Carr A; Smith D; Lewin SR; Wesselingh S; Cooper DA
J Infect Dis; 2004 Aug; 190(4):688-92. PubMed ID: 15272394
[TBL] [Abstract][Full Text] [Related]
18. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
19. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274
[TBL] [Abstract][Full Text] [Related]
20. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA; Lo Re V; O'Riordan M; Walker UA; Lebrecht D; Baron E; Mounzer K; Frank I
Clin Infect Dis; 2008 Apr; 46(8):1290-6. PubMed ID: 18444869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
